What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence indicates that venetoclax plus azacitidine improves overall survival compared to azacitidine or low dose cytarabine alone, particularly in patients with untreated acute myeloid leukaemia who are ineligible for intensive chemotherapy. The clinical trial data, while showing significant benefits, also highlight some uncertainty due to subgroup analyses that were not statistically powered to demonstrate clear clinical advantages. However, the overall survival benefit is compelling enough to warrant an A+ rating.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness analysis indicates that the ICER for venetoclax plus azacitidine is below £50,000 per QALY gained, which is within NICE’s acceptable range for cost-effectiveness. The treatment is considered a life-extending option at the end of life, further supporting its economic value.
Is there quality-of-life evidence payers weigh? — Quality of life
The treatment is expected to improve quality of life by allowing patients to manage side effects at home and reducing hospital visits. While specific HRQoL data is not extensively detailed, the potential for increased survival and the ability to manage treatment at home suggest moderate improvements in quality of life.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of venetoclax plus azacitidine is acceptable, with manageable adverse events reported. The committee noted that the adverse events were not significant enough to undermine the treatment’s benefits, leading to an overall good safety rating.
Was the drug compared against what payers expect? — Comparator Selection
The treatment was compared against appropriate standard-of-care alternatives, including azacitidine and low dose cytarabine. The use of relevant comparators strengthens the evidence base, although some subgroup analyses introduced additional uncertainty.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is considered broadly representative of the intended patient population, with subgroup analyses conducted to address specific clinical scenarios. However, there are some limitations in subgroup exploration, which slightly affects the rating.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
The treatment can be integrated into existing care pathways with minor adjustments, such as additional monitoring for adverse effects. The oral administration of venetoclax allows for reduced hospital visits, facilitating easier integration into patient care.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact is manageable, and the treatment is expected to be resource-efficient, particularly given the potential for reduced hospitalizations. The economic model suggests that the treatment is justifiable in terms of resource use.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is derived from a well-conducted randomized controlled trial, although there are some methodological concerns regarding subgroup analyses and the assumptions made in the economic model. Overall, the evidence is strong but not without limitations.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding the long-term outcomes and the cure assumption in the economic model, the context of unmet need and the potential benefits of the treatment mitigate some of these concerns. The overall societal context is favorable.
